GlaxoSmithKline Pharmaceuticals Limited has responded to queries regarding a significant increase in its security trading volume on stock exchanges. The company stated that it has made all necessary disclosures and has not withheld any material information. It clarified that the surge in volume is purely market-driven and assured stakeholders of its continued compliance with listing regulations.
Company Clarifies Trading Volume Surge
In response to an inquiry dated August 26, 2026, GlaxoSmithKline Pharmaceuticals Limited has provided clarification concerning a notable increase in the trading volume of its securities across exchanges. The company emphasized that it has consistently adhered to its disclosure obligations, including those under Regulation 30 of SEBI (LODR) Regulations, 2015.
No Withheld Information
GlaxoSmithKline Pharmaceuticals Limited affirmed that it has not withheld any material information or event that could potentially influence the Company’s operations or performance. All price-sensitive information has been duly disclosed.
Market-Driven Volume Increase
The Company attributed the significant rise in trading volume to purely market-driven factors. GlaxoSmithKline Pharmaceuticals Limited reiterated its commitment to complying with all prevailing listing regulations and will continue to promptly inform the Stock Exchange of any price-sensitive information as it arises.
Source: BSE
